Drugs / SK-1405
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02846181 | Jul → Aug 2016 | — | Sanwa Kagaku Kenkyusho Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02650076 | Jan → Apr 2016 | — | Sanwa Kagaku Kenkyusho Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03218501 Comparator | Aug 2017 → May 2018 | — | Sanwa Kagaku Kenkyusho Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SK-1405 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03218501 ↗ |
| Route | Oral | “a single PO dose of \[14C\]-SK-1405” NCT02846181 ↗ |